NCT05769478View on ClinicalTrials.gov

Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions
BotulismIatrogenic Botulism
Interventions
DRUG

Amifampridine

a single dose of amifampridine (20mg) will be orally administered

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT05769478 - Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA | Biotech Hunter | Biotech Hunter